About Acurx Pharmaceuticals
Acurx Pharmaceuticals (NASDAQ:ACXP) operates within the biotech industry focusing on the development of new antibiotics to combat bacterial infections, specifically targeting the treatment of Clostridioides difficile infections (CDI). The company is committed to advancing its lead candidate, ibezapolstat, through clinical trials aiming to offer a novel solution to address the rising global concern of antibiotic resistance. With a project pipeline designed to innovate and improve upon current treatment methodologies, Acurx Pharmaceuticals is actively working towards overcoming the challenges in treating bacterial infections effectively. Their objective remains steadfast in delivering breakthrough therapies to patients in need while striving for excellence in antibiotic drug development.
Snapshot
Operations
Products and/or services of Acurx Pharmaceuticals
- Ibezapolstat, an oral antibiotic for treating Clostridioides difficile infection (CDI) by specifically inhibiting bacterial replication without affecting gut microbiota.
- ACX-362E, a novel, oral antibiotic targeting DNA polymerase IIIC in Gram-positive bacteria, including multi-drug resistant strains.
- Preclinical antibiotic program focused on developing new treatments for bacterial infections resistant to current antibiotics, leveraging unique mechanisms of action.
- Collaborative research initiatives aimed at discovering and developing novel antimicrobial agents to combat antibiotic resistance.
- Participation in industry and academic partnerships to enhance the development pipeline and share expertise in drug development and antibiotic resistance.
- Investment in cutting-edge technology platforms to accelerate the discovery and development of next-generation antibiotics.
Acurx Pharmaceuticals executive team
- Mr. Robert J. DeLucciaCo-Founder & Executive Chairman
- Mr. David P. Luci CPA, Esq., J.D.Co-Founder, President, CEO, Corporate Secretary & Director
- Mr. Robert G. Shawah CPACo-Founder & CFO